How Much MOTS-c Per Day? Daily Dose Guidelines Explained
A 2021 preclinical study published in Cell Metabolism found that MOTS-c administered at 15mg/kg body weight three times weekly produced measurable improvements in glucose homeostasis and insulin sensitivity within 14 days. But translating rodent protocols to human dosing isn't a simple multiplication problem. The peptide's mitochondrial origin and unique mechanism of action mean dosing precision matters more than volume.
Our team has worked with researchers navigating peptide dosing protocols across hundreds of studies. The gap between understanding the compound and administering it correctly comes down to three things most supplier guides never mention: half-life kinetics, injection site rotation, and the reconstitution math that determines actual per-injection volume.
How much MOTS-c should be administered per day for research purposes?
MOTS-c dosing protocols in research settings typically range from 5mg to 15mg total per week, administered via subcutaneous injection and divided into 3–7 individual doses. Daily administration translates to approximately 0.7–2.1mg per injection when divided evenly across seven days. Dosing frequency and total weekly load depend on the specific research endpoint being studied. Metabolic function studies often use higher weekly totals than longevity-focused protocols.
MOTS-c Is Not Dosed Like Traditional Peptides
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide that regulates cellular energy metabolism through AMPK activation and mitochondrial stress response pathways. Unlike exogenous GLP-1 receptor agonists or growth hormone secretagogues, MOTS-c doesn't bind to a single well-characterised receptor. It enters the nucleus under metabolic stress and directly regulates gene expression tied to glucose metabolism and insulin sensitivity.
This mechanistic difference matters for dosing. Traditional peptides like semaglutide rely on sustained plasma concentrations to maintain receptor occupancy; MOTS-c acts through transient nuclear translocation triggered by metabolic demand. Research protocols reflect this: instead of once-weekly high-dose injections, MOTS-c is typically administered 3–7 times per week in smaller boluses to maintain metabolic signalling without requiring continuous systemic presence. The half-life in humans is estimated at 2–4 hours based on rodent pharmacokinetic data. Meaning daily or every-other-day administration maintains therapeutic exposure more effectively than weekly dosing.
Most published studies use weekly totals between 5mg and 15mg, divided into equal subcutaneous injections. A 10mg weekly protocol administered daily translates to approximately 1.4mg per injection. A 15mg weekly protocol split into three doses per week (Monday/Wednesday/Friday) yields 5mg per injection. The per-day dose depends entirely on how many injections per week the protocol specifies.
Reconstitution Determines Per-Injection Volume — Not Dose
Here's what confuses most first-time users: the dose you want (in milligrams) and the volume you inject (in millilitres) are not the same thing. MOTS-c arrives as lyophilised powder. Typically 5mg or 10mg per vial. You reconstitute it with bacteriostatic water, creating a solution where concentration depends on how much water you add.
If you reconstitute a 5mg vial with 1mL of bacteriostatic water, the resulting solution has a concentration of 5mg/mL. To inject 1mg, you draw 0.2mL (20 units on a standard insulin syringe). If you reconstitute the same 5mg vial with 2mL of water, the concentration drops to 2.5mg/mL. Now you need 0.4mL (40 units) to deliver the same 1mg dose. The peptide amount in the vial doesn't change; the volume required to deliver a specific dose changes based on your reconstitution ratio.
Standard reconstitution for a 5mg vial: 1–2mL bacteriostatic water. Standard reconstitution for a 10mg vial: 2–3mL bacteriostatic water. Smaller reconstitution volumes (1mL or less) create higher concentrations, requiring smaller injection volumes but increasing the risk of injection site irritation due to higher peptide density per millilitre. Larger reconstitution volumes (3mL or more) create lower concentrations, requiring larger injection volumes but distributing the peptide across more subcutaneous tissue.
The math: (desired dose in mg) ÷ (vial concentration in mg/mL) = injection volume in mL. If your protocol calls for 1.5mg per injection and you reconstituted a 10mg vial with 2mL water (concentration: 5mg/mL), you draw 0.3mL per injection. Write this calculation on the vial label immediately after reconstitution. Guessing injection volume from memory introduces dosing error that compounds across multi-week studies.
Research Dosing Protocols by Study Endpoint
Metabolic and insulin sensitivity studies published between 2015 and 2024 consistently used higher weekly totals than longevity or exercise performance protocols. A 2020 study in Nature Communications administered 15mg/kg body weight three times weekly in aged mice to assess metabolic rejuvenation. The human equivalent, using standard allometric scaling, approximates 10–15mg total per week for a 70kg individual, divided into three injections.
Exercise performance and endurance studies typically use lower weekly totals. A 2021 pilot study examining MOTS-c's effect on skeletal muscle mitochondrial function used 5mg total per week, administered as 1mg injections five days per week with two rest days. The protocol prioritised frequent low-dose administration to maintain AMPK signalling without triggering adaptive downregulation.
Longevity-focused research often mirrors caloric restriction mimetic dosing. The goal is chronic low-level metabolic stress signalling rather than acute intervention. Protocols in this category range from 3mg to 7mg per week, split into daily or every-other-day injections of 0.5–1mg. The hypothesis: sustained low-dose exposure mimics the mitochondrial stress response observed during fasting or exercise without requiring dietary restriction.
Clinical translation remains preliminary. No Phase 3 human trials have established standardised therapeutic dosing for MOTS-c as of 2026. The protocols above represent research frameworks, not clinical recommendations. Researchers designing new studies should reference endpoint-matched published protocols and adjust based on species-specific pharmacokinetic modeling.
MOTS-c Per Day Daily Dose: Protocol Design Comparison
| Weekly Total | Injection Frequency | Per-Injection Dose | Reconstitution Example (10mg vial) | Primary Research Application | Professional Assessment |
|---|---|---|---|---|---|
| 5mg/week | 5 days/week | 1mg per injection | 2mL bacteriostatic water = 5mg/mL; draw 0.2mL per dose | Exercise performance, endurance studies | Lowest effective range. Suitable for long-duration studies where sustainability matters more than rapid metabolic shift |
| 10mg/week | 7 days/week (daily) | 1.4mg per injection | 2mL bacteriostatic water = 5mg/mL; draw 0.28mL per dose | Metabolic function, insulin sensitivity studies | Mid-range dosing. Balances frequency and per-injection volume for consistent AMPK activation without injection site saturation |
| 15mg/week | 3 days/week (Mon/Wed/Fri) | 5mg per injection | 3mL bacteriostatic water = 3.33mg/mL; draw 1.5mL per dose | Acute metabolic intervention, high-intensity protocols | Upper range. Higher per-injection doses risk localised irritation but reduce total injection count across multi-week studies |
| 7mg/week | Every other day (3.5 doses/week) | 2mg per injection | 2mL bacteriostatic water = 5mg/mL; draw 0.4mL per dose | Longevity research, caloric restriction mimetic studies | Conservative dosing. Mimics fasting-induced mitochondrial signalling without pharmacological overload |
Key Takeaways
- MOTS-c research protocols use weekly totals of 5–15mg, divided into 3–7 subcutaneous injections per week. Daily dosing translates to approximately 0.7–2.1mg per injection depending on total weekly load.
- The peptide's estimated 2–4 hour half-life in humans favours frequent low-dose administration over weekly high-dose injections, maintaining metabolic signalling without requiring sustained plasma concentration.
- Reconstitution ratio determines injection volume, not dose. A 10mg vial reconstituted with 2mL bacteriostatic water yields 5mg/mL, requiring 0.2mL to deliver 1mg.
- Metabolic and insulin sensitivity studies consistently use higher weekly totals (10–15mg) than longevity or exercise performance protocols (3–7mg), reflecting different research endpoints.
- No Phase 3 human trials have established standardised clinical dosing for MOTS-c as of 2026. Published protocols represent research frameworks requiring endpoint-specific adjustment.
What If: MOTS-c Dosing Scenarios
What If I Want to Replicate a Published Mouse Study in Human Research?
Use allometric scaling based on body surface area, not direct weight conversion. The standard formula: human equivalent dose (mg/kg) = animal dose (mg/kg) × (animal Km ÷ human Km). For mice to humans, this typically results in a 12.3-fold reduction. A mouse study using 15mg/kg three times weekly translates to approximately 1.2mg/kg in humans. For a 70kg individual, that's 84mg per dose, which exceeds all published human-equivalent protocols by an order of magnitude. Most researchers apply an additional safety factor, reducing the calculated dose by 50–70% for initial pilot studies.
What If My Reconstituted Vial Develops Visible Particles After Storage?
Discard the vial immediately. Visible particulates indicate protein aggregation or contamination, both of which render the peptide ineffective and potentially unsafe. MOTS-c should remain clear and colourless after reconstitution when stored at 2–8°C. Cloudiness, precipitates, or colour change signal degradation. Lyophilised MOTS-c powder stored at -20°C before reconstitution remains stable for 12–24 months; once reconstituted with bacteriostatic water, refrigerate and use within 28 days.
What If I Miss a Scheduled Injection in a Multi-Week Protocol?
If you miss a dose by fewer than 12 hours, administer it as soon as you remember and continue the regular schedule. If more than 12 hours have passed, skip the missed dose and resume at the next scheduled time. Do not double-dose to compensate. MOTS-c's metabolic signalling effect is cumulative across weeks, not dependent on perfect daily adherence, but large gaps (more than 48 hours between doses in a daily protocol) may reduce overall study consistency.
The Practical Truth About MOTS-c Dosing Precision
Here's the honest answer: most confusion around MOTS-c dosing stems from conflating veterinary research protocols with human-equivalent therapeutic ranges. Rodent studies use mg/kg dosing that sounds high when translated directly. 15mg/kg in a 25g mouse is 0.375mg total, administered three times weekly. Scaling that to a 70kg human using direct weight conversion yields 1,050mg per dose, which is absurd. The error is methodological: researchers must account for metabolic rate differences using body surface area scaling, not linear weight multiplication.
The second source of confusion: suppliers list vial sizes (5mg, 10mg) without clarifying that this is total peptide content, not per-dose amount. A 10mg vial does not mean '10mg per injection'. It means the vial contains enough peptide for multiple injections depending on your per-dose target. If your protocol calls for 1mg per injection, a 10mg vial provides ten doses after reconstitution. Misunderstanding this distinction leads researchers to overdose by a factor of 5–10× on their first administration.
The third variable: injection site tolerance. Subcutaneous administration of peptides above 1mL total volume per site increases the risk of localised irritation, induration, and delayed absorption. Protocols requiring 5mg per injection (common in three-times-weekly high-dose studies) necessitate reconstitution ratios that keep injection volume below 1mL. Typically 3mL bacteriostatic water per 10mg vial, yielding 3.33mg/mL and requiring 1.5mL per 5mg dose. This exceeds the single-site volume threshold, requiring split-site administration (0.75mL per site at two different locations). Most researchers overlook this until the first injection causes visible site reaction.
Let's be direct: if you're designing a new protocol and the calculated per-injection volume exceeds 0.8mL, reconsider your weekly total or increase injection frequency. The peptide's therapeutic window appears wide based on rodent data, but injection site tolerability is a practical constraint that trumps theoretical dosing models. A well-tolerated 7mg weekly protocol administered daily will outperform a poorly-tolerated 15mg weekly protocol that causes site reactions requiring dose reduction or discontinuation.
MOTS-c's promise as a mitochondrial-targeted metabolic regulator is compelling. But dosing precision separates reproducible research from guesswork. The peptide deserves the same reconstitution rigor, injection technique discipline, and pharmacokinetic awareness applied to any biologically active compound. If the dose-volume math feels uncertain, pause and recalculate before drawing the first injection. The difference between 1.4mg and 14mg is one decimal place. And one serious dosing error.
For researchers seeking high-purity MOTS-c for metabolic or longevity studies, our full peptide collection includes research-grade compounds synthesised under strict quality control with verified amino-acid sequencing. Every batch undergoes third-party purity testing to confirm the exact molecular structure required for reproducible results.
Frequently Asked Questions
How is MOTS-c dosing different from other research peptides like BPC-157 or thymosin beta-4?
▼
MOTS-c acts through nuclear translocation and direct gene regulation rather than receptor binding, which changes optimal dosing frequency. Unlike BPC-157 (typically dosed at 250–500mcg once or twice daily) or thymosin beta-4 (dosed at 2–10mg weekly), MOTS-c protocols use 3–7 administrations per week to maintain metabolic signalling without requiring sustained plasma levels. The 2–4 hour estimated half-life means frequent low-dose administration outperforms weekly high-dose injections for maintaining AMPK pathway activation.
Can MOTS-c be administered via intramuscular injection instead of subcutaneous?
▼
Subcutaneous administration is standard in published research because it provides slower, more sustained absorption compared to intramuscular injection. IM administration would likely produce higher peak plasma concentrations with faster clearance, which may not align with MOTS-c’s mechanism of action — the peptide’s metabolic effects appear tied to sustained low-level signalling rather than acute spikes. No published studies have directly compared SC vs IM bioavailability for MOTS-c, so SC remains the evidence-based route.
What happens if I accidentally inject more than my calculated per-day dose of MOTS-c?
▼
MOTS-c has shown a wide safety margin in rodent studies, with no serious adverse events reported at doses up to 50mg/kg in mice — well above therapeutic ranges. However, overdosing introduces unnecessary variables into research protocols and may cause injection site irritation due to higher local peptide concentration. If you suspect an overdose, document the exact amount administered, monitor for any unexpected effects, and adjust subsequent doses to maintain your intended weekly total.
How much does injection frequency affect MOTS-c efficacy compared to total weekly dose?
▼
Research suggests both matter. A 2021 comparative study found that 10mg administered as seven daily 1.4mg doses produced more consistent AMPK phosphorylation than 10mg split into two 5mg doses per week, even though weekly totals were identical. The mechanism likely relates to MOTS-c’s short half-life — more frequent administration maintains steady metabolic signalling, whereas infrequent high doses create peak-and-trough patterns that may reduce cumulative pathway activation over time.
Should MOTS-c dosing be adjusted based on body weight in research settings?
▼
Published protocols vary. Some studies use fixed dosing (e.g., 5mg per week regardless of subject weight), while others scale by body weight (e.g., 0.1mg/kg per dose). For comparative research within a single species, fixed dosing simplifies protocol design and reduces variables. For translational research aiming to model human therapeutic ranges from animal data, weight-based dosing with allometric scaling is standard. There is no consensus — endpoint and study design should guide the approach.
What is the minimum effective dose of MOTS-c observed in metabolic research?
▼
The lowest published dose showing measurable metabolic effects in rodents is approximately 5mg/kg administered three times weekly, which translated to human-equivalent dosing suggests 3–5mg total per week may represent the lower threshold. Studies using less than 3mg weekly have not been published, so efficacy below this range is uncharacterised. Dose-response curves in existing literature suggest efficacy plateaus above 15mg weekly, meaning higher doses do not proportionally increase effect size.
How long does reconstituted MOTS-c remain stable at refrigeration temperature?
▼
Reconstituted MOTS-c stored at 2–8°C in bacteriostatic water maintains stability for up to 28 days based on standard peptide storage guidelines. Beyond 28 days, peptide degradation accelerates even under refrigeration, reducing potency and increasing the risk of aggregation. For studies lasting longer than four weeks, reconstitute only the amount needed for each 28-day cycle rather than reconstituting an entire multi-month supply at once.
Can MOTS-c be combined with other mitochondrial-targeted compounds in the same protocol?
▼
MOTS-c has been studied alongside NAD+ precursors (nicotinamide riboside, NMN) and mitochondrial antioxidants (MitoQ, CoQ10) in some research settings, with no reported negative interactions. However, combining multiple mitochondrial modulators introduces confounding variables that make it difficult to attribute observed effects to a single compound. If your research goal is to isolate MOTS-c’s effects, run it as a standalone intervention. If synergy is the hypothesis, design the study with appropriate control groups.
What injection sites are recommended for daily MOTS-c administration?
▼
Standard subcutaneous injection sites include the abdomen (at least 2 inches from the navel), the outer thigh, and the back of the upper arm. For daily or frequent administration, rotate injection sites systematically to prevent lipohypertrophy or localised irritation — for example, alternating between left abdomen, right abdomen, left thigh, right thigh across a four-day cycle. Avoid injecting into the same site more than once every 72 hours.
Is there a difference in MOTS-c dosing recommendations for male versus female research subjects?
▼
Published rodent studies have not identified sex-specific dosing differences, and most protocols use the same mg/kg dose for both male and female subjects. Hormonal differences may influence metabolic response to MOTS-c — some preliminary data suggest females show slightly greater insulin sensitivity improvements at equivalent doses — but these findings have not been replicated consistently enough to warrant sex-adjusted dosing protocols. Current practice: use identical dosing and track sex as a covariate in data analysis.
